Biocryst Pharmaceuticals Inc Financials
This page shows Biocryst Pharmaceuticals Inc (BCRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Biocryst Pharmaceuticals Inc has an operating margin of 39.0%, meaning the company retains $39 of operating profit per $100 of revenue. This strong profitability earns a score of 100/100, reflecting efficient cost management and pricing power. This is up from -0.6% the prior year.
Biocryst Pharmaceuticals Inc's revenue surged 94.1% year-over-year to $874.8M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Biocryst Pharmaceuticals Inc's current ratio of 2.06 indicates adequate short-term liquidity, earning a score of 37/100. The company can meet its near-term obligations, though with limited headroom.
Biocryst Pharmaceuticals Inc converts 39.4% of revenue into free cash flow ($344.9M). This strong cash generation earns a score of 100/100.
Biocryst Pharmaceuticals Inc scores 2.42, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($2.3B) relative to total liabilities ($633.3M). This signals moderate financial risk that warrants monitoring.
Biocryst Pharmaceuticals Inc passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Biocryst Pharmaceuticals Inc generates $1.32 in operating cash flow ($347.4M OCF vs $263.9M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Biocryst Pharmaceuticals Inc earns $4.3 in operating income for every $1 of interest expense ($341.0M vs $78.9M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.
Key Financial Metrics
Earnings & Revenue
Biocryst Pharmaceuticals Inc generated $874.8M in revenue in fiscal year 2025. This represents an increase of 94.1% from the prior year.
Biocryst Pharmaceuticals Inc's EBITDA was $342.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 26497.7% from the prior year.
Biocryst Pharmaceuticals Inc reported $263.9M in net income in fiscal year 2025. This represents an increase of 396.9% from the prior year.
Biocryst Pharmaceuticals Inc earned $1.21 per diluted share (EPS) in fiscal year 2025. This represents an increase of 381.4% from the prior year.
Cash & Balance Sheet
Biocryst Pharmaceuticals Inc generated $344.9M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 749.0% from the prior year.
Biocryst Pharmaceuticals Inc held $89.7M in cash against $0 in long-term debt as of fiscal year 2025.
Biocryst Pharmaceuticals Inc had 213M shares outstanding in fiscal year 2025. This represents an increase of 2.2% from the prior year.
Margins & Returns
Biocryst Pharmaceuticals Inc's gross margin was 97.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.5 percentage points from the prior year.
Biocryst Pharmaceuticals Inc's operating margin was 39.0% in fiscal year 2025, reflecting core business profitability. This is up 39.5 percentage points from the prior year.
Biocryst Pharmaceuticals Inc's net profit margin was 30.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 49.9 percentage points from the prior year.
Capital Allocation
Biocryst Pharmaceuticals Inc invested $166.1M in research and development in fiscal year 2025. This represents a decrease of 4.9% from the prior year.
Biocryst Pharmaceuticals Inc invested $2.5M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 119.6% from the prior year.
BCRX Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $406.6M+155.1% | $159.4M-2.4% | $163.4M+12.2% | $145.5M+10.6% | $131.5M+12.3% | $117.1M+7.1% | $109.3M+17.9% | $92.8M |
| Cost of Revenue | $9.5M+335.4% | $2.2M-21.8% | $2.8M-38.7% | $4.6M-25.0% | $6.1M+89.8% | $3.2M+89.0% | $1.7M+34.3% | $1.3M |
| Gross Profit | $397.0M+152.6% | $157.2M-2.1% | $160.6M+13.9% | $141.0M+12.4% | $125.4M+10.2% | $113.9M+5.8% | $107.6M+17.6% | $91.5M |
| R&D Expenses | $40.9M-8.4% | $44.6M+2.8% | $43.4M+16.4% | $37.3M-24.6% | $49.4M+20.4% | $41.1M+9.2% | $37.6M-19.1% | $46.5M |
| SG&A Expenses | $95.8M+15.4% | $83.0M-5.0% | $87.4M+6.0% | $82.5M+2.4% | $80.5M+23.7% | $65.1M+6.3% | $61.2M+3.0% | $59.5M |
| Operating Income | $260.4M+779.9% | $29.6M-0.7% | $29.8M+40.3% | $21.2M+570.9% | -$4.5M-158.6% | $7.7M-12.2% | $8.8M+160.5% | -$14.5M |
| Interest Expense | $14.1M-28.1% | $19.7M-8.9% | $21.6M-8.1% | $23.5M-3.9% | $24.4M-1.5% | $24.8M+0.4% | $24.7M+0.9% | $24.5M |
| Income Tax | $2.2M+382.4% | -$769K-154.9% | $1.4M+93.0% | $726K-9.7% | $804K+37.2% | $586K+240.7% | $172K-52.9% | $365K |
| Net Income | $245.8M+1805.9% | $12.9M+153.7% | $5.1M+15790.6% | $32K+100.1% | -$26.8M-90.9% | -$14.0M-10.7% | -$12.7M+64.2% | -$35.4M |
| EPS (Diluted) | N/A | $0.06+200.0% | $0.02 | $0.00 | N/A | $-0.07-16.7% | $-0.06+64.7% | $-0.17 |
BCRX Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $514.2M+15.2% | $446.4M-2.4% | $457.2M-4.8% | $480.0M-2.1% | $490.4M-0.2% | $491.3M+4.0% | $472.4M+1.0% | $467.9M |
| Current Assets | $404.3M+13.7% | $355.7M-10.7% | $398.5M-2.8% | $410.0M-2.8% | $422.0M-1.2% | $427.1M+17.5% | $363.5M-18.7% | $447.1M |
| Cash & Equivalents | $89.7M+6.7% | $84.1M-4.5% | $88.0M-16.3% | $105.2M+0.5% | $104.7M+8.1% | $96.8M+23.5% | $78.4M-7.0% | $84.3M |
| Inventory | $5.4M+3.2% | $5.2M+3.7% | $5.0M-26.6% | $6.9M-15.0% | $8.1M+6.9% | $7.6M+69.9% | $4.5M-85.1% | $29.8M |
| Accounts Receivable | $106.8M+17.0% | $91.3M+0.2% | $91.2M-2.4% | $93.4M+18.1% | $79.1M+9.1% | $72.5M+5.4% | $68.8M+13.5% | $60.6M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $633.3M-24.1% | $834.3M-5.1% | $878.8M-5.7% | $932.0M-3.6% | $966.4M+0.7% | $959.8M+1.2% | $948.0M+0.4% | $944.1M |
| Current Liabilities | $196.1M+3.1% | $190.2M+7.4% | $177.2M+26.7% | $139.9M-12.8% | $160.4M+4.4% | $153.6M+19.0% | $129.1M+7.6% | $119.9M |
| Long-Term Debt | $0-100.0% | $194.4M-19.9% | $242.8M-23.0% | $315.4M+0.2% | $314.9M+0.2% | $314.3M+0.2% | $313.8M+1.7% | $308.5M |
| Total Equity | -$119.2M+69.3% | -$387.9M+8.0% | -$421.6M+6.7% | -$451.9M+5.0% | -$475.9M-1.6% | -$468.6M+1.5% | -$475.6M+0.1% | -$476.2M |
| Retained Earnings | -$1.5B+14.0% | -$1.8B+0.7% | -$1.8B+0.3% | -$1.8B0.0% | -$1.8B-1.5% | -$1.7B-0.8% | -$1.7B-0.7% | -$1.7B |
BCRX Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $292.0M+601.4% | $41.6M+0.8% | $41.3M+250.1% | -$27.5M-427.9% | -$5.2M-163.2% | $8.2M+702.7% | -$1.4M+97.5% | -$53.7M |
| Capital Expenditures | $802K-40.3% | $1.3M+650.8% | $179K+25.2% | $143K-78.8% | $675K+1044.1% | $59K-61.9% | $155K-34.0% | $235K |
| Free Cash Flow | $291.2M+622.8% | $40.3M-2.0% | $41.1M+248.7% | -$27.7M-369.8% | -$5.9M-171.9% | $8.2M+637.5% | -$1.5M+97.2% | -$53.9M |
| Investing Cash Flow | -$83.5M-715.1% | $13.6M-53.4% | $29.1M+7.5% | $27.1M+52.2% | $17.8M+109.6% | $8.5M+446.6% | -$2.4M-108.5% | $28.8M |
| Financing Cash Flow | -$218.0M-270.6% | -$58.8M+20.2% | -$73.7M-14029.3% | $529K+113.2% | -$4.0M-415.6% | $1.3M+164.8% | -$2.0M-87.6% | -$1.0M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
BCRX Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 97.7%-1.0pp | 98.6%+0.3pp | 98.3%+1.4pp | 96.9%+1.5pp | 95.4%-1.9pp | 97.3%-1.2pp | 98.5%-0.2pp | 98.6% |
| Operating Margin | 64.0%+45.5pp | 18.6%+0.3pp | 18.2%+3.6pp | 14.6%+18.0pp | -3.4%-10.0pp | 6.6%-1.4pp | 8.0%+23.6pp | -15.6% |
| Net Margin | 60.5%+52.4pp | 8.1%+5.0pp | 3.1%+3.1pp | 0.0%+20.4pp | -20.4%-8.4pp | -12.0%-0.4pp | -11.6%+26.6pp | -38.1% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | 47.8%+44.9pp | 2.9%+1.8pp | 1.1%+1.1pp | 0.0%+5.5pp | -5.5%-2.6pp | -2.9%-0.2pp | -2.7%+4.9pp | -7.6% |
| Current Ratio | 2.06+0.2 | 1.87-0.4 | 2.25-0.7 | 2.93+0.3 | 2.63-0.2 | 2.78-0.0 | 2.82-0.9 | 3.73 |
| Debt-to-Equity | 0.00+0.5 | -0.50+0.1 | -0.58+0.1 | -0.70-0.0 | -0.660.0 | -0.67-0.0 | -0.66-0.0 | -0.65 |
| FCF Margin | 71.6%+46.3pp | 25.3%+0.1pp | 25.2%+44.2pp | -19.0%-14.5pp | -4.5%-11.5pp | 7.0%+8.4pp | -1.4%+56.7pp | -58.1% |
Note: Shareholder equity is negative (-$119.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Frequently Asked Questions
What is Biocryst Pharmaceuticals Inc's annual revenue?
Biocryst Pharmaceuticals Inc (BCRX) reported $874.8M in total revenue for fiscal year 2025. This represents a 94.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Biocryst Pharmaceuticals Inc's revenue growing?
Biocryst Pharmaceuticals Inc (BCRX) revenue grew by 94.1% year-over-year, from $450.7M to $874.8M in fiscal year 2025.
Is Biocryst Pharmaceuticals Inc profitable?
Yes, Biocryst Pharmaceuticals Inc (BCRX) reported a net income of $263.9M in fiscal year 2025, with a net profit margin of 30.2%.
What is Biocryst Pharmaceuticals Inc's EBITDA?
Biocryst Pharmaceuticals Inc (BCRX) had EBITDA of $342.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Biocryst Pharmaceuticals Inc have?
As of fiscal year 2025, Biocryst Pharmaceuticals Inc (BCRX) had $89.7M in cash and equivalents against $0 in long-term debt.
What is Biocryst Pharmaceuticals Inc's gross margin?
Biocryst Pharmaceuticals Inc (BCRX) had a gross margin of 97.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Biocryst Pharmaceuticals Inc's operating margin?
Biocryst Pharmaceuticals Inc (BCRX) had an operating margin of 39.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Biocryst Pharmaceuticals Inc's net profit margin?
Biocryst Pharmaceuticals Inc (BCRX) had a net profit margin of 30.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Biocryst Pharmaceuticals Inc's free cash flow?
Biocryst Pharmaceuticals Inc (BCRX) generated $344.9M in free cash flow during fiscal year 2025. This represents a 749.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Biocryst Pharmaceuticals Inc's operating cash flow?
Biocryst Pharmaceuticals Inc (BCRX) generated $347.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Biocryst Pharmaceuticals Inc's total assets?
Biocryst Pharmaceuticals Inc (BCRX) had $514.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Biocryst Pharmaceuticals Inc's capital expenditures?
Biocryst Pharmaceuticals Inc (BCRX) invested $2.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Biocryst Pharmaceuticals Inc spend on research and development?
Biocryst Pharmaceuticals Inc (BCRX) invested $166.1M in research and development during fiscal year 2025.
What is Biocryst Pharmaceuticals Inc's current ratio?
Biocryst Pharmaceuticals Inc (BCRX) had a current ratio of 2.06 as of fiscal year 2025, which is generally considered healthy.
What is Biocryst Pharmaceuticals Inc's debt-to-equity ratio?
Biocryst Pharmaceuticals Inc (BCRX) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Biocryst Pharmaceuticals Inc's return on assets (ROA)?
Biocryst Pharmaceuticals Inc (BCRX) had a return on assets of 51.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Why is Biocryst Pharmaceuticals Inc's debt-to-equity ratio negative or unusual?
Biocryst Pharmaceuticals Inc (BCRX) has negative shareholder equity of -$119.2M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Biocryst Pharmaceuticals Inc's Altman Z-Score?
Biocryst Pharmaceuticals Inc (BCRX) has an Altman Z-Score of 2.42, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Biocryst Pharmaceuticals Inc's Piotroski F-Score?
Biocryst Pharmaceuticals Inc (BCRX) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Biocryst Pharmaceuticals Inc's earnings high quality?
Biocryst Pharmaceuticals Inc (BCRX) has an earnings quality ratio of 1.32x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Biocryst Pharmaceuticals Inc cover its interest payments?
Biocryst Pharmaceuticals Inc (BCRX) has an interest coverage ratio of 4.3x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Biocryst Pharmaceuticals Inc?
Biocryst Pharmaceuticals Inc (BCRX) scores 84 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.